177 related articles for article (PubMed ID: 34312687)
21. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
[TBL] [Abstract][Full Text] [Related]
22. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; Qiu D; Kitajima H; Mittal PK; Kim HS
Abdom Imaging; 2014 Oct; 39(5):969-78. PubMed ID: 24740759
[TBL] [Abstract][Full Text] [Related]
23. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization.
Bargellini I; Crocetti L; Turini FM; Lorenzoni G; Boni G; Traino AC; Caramella D; Cioni R
Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1373-1383. PubMed ID: 29654507
[TBL] [Abstract][Full Text] [Related]
24. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
25. Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy: a simple semi-quantitative analysis.
Cheng B; Sethi I; Villalobos A; Wagstaff W; Schuster DM; Bercu Z; Brandon D; Kokabi N
Nucl Med Commun; 2021 Aug; 42(8):892-898. PubMed ID: 33795611
[TBL] [Abstract][Full Text] [Related]
26. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
[TBL] [Abstract][Full Text] [Related]
27. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
[TBL] [Abstract][Full Text] [Related]
28. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
[TBL] [Abstract][Full Text] [Related]
29. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
30. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria.
Ghosn M; Derbel H; Kharrat R; Oubaya N; Mulé S; Chalaye J; Regnault H; Amaddeo G; Itti E; Luciani A; Kobeiter H; Tacher V
Diagn Interv Imaging; 2021 Jan; 102(1):35-44. PubMed ID: 33012693
[TBL] [Abstract][Full Text] [Related]
31. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
32. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
33. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival.
Somma F; Stoia V; Serra N; D'Angelo R; Gatta G; Fiore F
PLoS One; 2019; 14(5):e0216935. PubMed ID: 31141552
[TBL] [Abstract][Full Text] [Related]
34. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study.
Mazzaferro V; Sposito C; Bhoori S; Romito R; Chiesa C; Morosi C; Maccauro M; Marchianò A; Bongini M; Lanocita R; Civelli E; Bombardieri E; Camerini T; Spreafico C
Hepatology; 2013 May; 57(5):1826-37. PubMed ID: 22911442
[TBL] [Abstract][Full Text] [Related]
35. Single-Center Comparison of Overall Survival and Toxicities in Patients with Infiltrative Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization or Drug-Eluting Embolic Transarterial Chemoembolization.
McDevitt JL; Alian A; Kapoor B; Bennett S; Gill A; Levitin A; Sands M; Narayanan Menon KV; Aucejo FN; Estfan B; Pillai AK; Kalva SP; McLennan G
J Vasc Interv Radiol; 2017 Oct; 28(10):1371-1377. PubMed ID: 28689934
[TBL] [Abstract][Full Text] [Related]
36. Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma.
Mora RA; Ali R; Gabr A; Abouchaleh N; Asadi AA; Kallini JR; Miller FH; Yaghmai V; Mouli S; Thornburg B; Desai K; Riaz A; Lewandowski RJ; Salem R
Abdom Radiol (NY); 2018 Jul; 43(7):1723-1738. PubMed ID: 29147766
[TBL] [Abstract][Full Text] [Related]
37. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.
Gui B; Weiner AA; Nosher J; Lu SE; Foltz GM; Hasan O; Kim SK; Gendel V; Mani NB; Carpizo DR; Saad NE; Kennedy TJ; Zuckerman DA; Olsen JR; Parikh PJ; Jabbour SK
Am J Clin Oncol; 2018 Sep; 41(9):861-866. PubMed ID: 28418940
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
[TBL] [Abstract][Full Text] [Related]
40. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]